Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

SHAREHOLDER ALERT: Weiss Law Reminds SBTX, LJPC, CNVY, and DRE Shareholders About Its Ongoing Investigations

SBTX, CNVY

NEW YORK, July 28, 2022 /PRNewswire/ --

(PRNewsfoto/WeissLaw LLP)

If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
Weiss Law
305 Broadway, 7th Floor
New York, NY 10007
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

Silverback Therapeutics, Inc. (NASDAQ: SBTX)

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Silverback Therapeutics, Inc. (NASDAQ: SBTX), in connection with SBTX's proposed merger with ARS Pharmaceuticals, Inc. ("ARS"). Under the terms of the merger agreement, assuming that SBTX's net cash at closing is $240 million, SBTX equity holders are expected to own only approximately 37% of the combined company and pre-merger ARS equity holders are expected to own approximately 63% of the combined company. If you own SBTX shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/sbtx

La Jolla Pharmaceutical Company (NASDAQ: LJPC)

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of La Jolla Pharmaceutical Company (NASDAQ: LJPC) in connection with the proposed acquisition of LJPC by Innoviva, Inc. via tender offer. Under the terms of the merger agreement, LJPC shareholders will receive $6.23 in cash for each share of LJPC common stock owned. If you own LJPC shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/ljpc

Convey Health Solutions Holdings, Inc. (NYSE: CNVY)

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Convey Health Solutions Holdings, Inc. (NYSE: CNVY), in connection with the proposed acquisition of CNVY by TPG Capital. Under the terms of the merger agreement, CNVY shareholders will receive $10.50 in cash for each share of CNVY common stock owned. If you own CNVY shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/cnvy

Duke Realty Corporation (NYSE: DRE)

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Duke Realty Corporation (NYSE: DRE), in connection with the proposed acquisition of DRE by Prologis, Inc. ("Prologis"). Upon completion of the transaction, DRE shareholders will receive 0.475 shares of Prologis common stock for each DRE share owned, representing implied per-share merger consideration of approximately $60.51 based upon Prologis's July 27, 2022 closing price of $127.39. If you own DRE shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/dre

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-weiss-law-reminds-sbtx-ljpc-cnvy-and-dre-shareholders-about-its-ongoing-investigations-301595639.html

SOURCE Weiss Law